# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain in...
XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, d...
XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized...
Gainers
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market ope...